Disposition and Absolute Bioavailability of Oral Imlunestrant in Healthy Women: A Phase 1, Open-Label Study

• Published in: Clinical pharmacology in drug development
• Main Authors: Datta-Mannan, Amita, Czeskis, Boris, Shanks, Elaine, Yuen, Eunice, Hall, Stephen, Rodriguez Cruz, Vivian, Cassidy, Kenneth
• Format: Journal Article
• Language: English
• Published: United States 24.06.2025
• Subjects: imlunestrant; disposition; absolute bioavailability; microtracer; pharmacokinetics; selective estrogen receptor degraders; breast cancer

Imlunestrant (LY3484356) is a next-generation orally bioavailable selective estrogen receptor degrader being investigated for the treatment of estrogen receptor-positive advanced breast and endometrial cancers. This Phase 1, open-label, 2-part study evaluated the disposition and absolute bioavailabi...